Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aegerion Pharmaceuticals Inc Reaffirms FY 2013 Global Net Revenues Guidance


Wednesday, 6 Mar 2013 07:00am EST 

Aegerion Pharmaceuticals Inc confirmed the previously stated financial guidance and expects global net revenues of $15 million to $25 million for fiscal 2013 with 250 to 300 patients on JUXTAPID therapy globally by year-end 2013. In the second half of 2014, the Company expects to generate global net revenue at a $100 million annualized run rate; and achieve cash flow breakeven from operations. 

Company Quote

30.14
0.03 +0.10%
22 Aug 2014